Applied Evidence

Asthma: Newer Tx options mean more targeted therapy

Author and Disclosure Information

 

References

Glycopyrronium bromide (glycopyrrolate, multiple brand names) and umeclidinium (Incruse Ellipta) are LAMAs that are approved for COPD treatment but have not yet been approved for patients who have asthma only.31

Biological therapies

In the past few years, improved understanding of asthma’s pathophysiology has led to the development of biological therapy for severe asthma. This therapy is directed at Th-2 inflammatory pathways (FIGURE) and targets various inflammatory markers, such as IgE, IL-5, and eosinophils.

Biologicals are not the first-line therapy for the management of severe asthma. Ideal candidates for this therapy are patients who have exhausted other forms of severe asthma treatment, including ICS-LABA, LAMA, leukotriene receptor antagonists, and mucus-clearing agents. Patients with frequent exacerbations who need continuous steroids or need steroids at least twice a year should be considered for biologicals.32

All biological therapies must be administered in a clinical setting, as they carry risk for anaphylaxis. TABLE 315,33-47 summarizes all approved biologicals for the management of severe asthma.

Comparison of FDA-approved biological therapies for severe asthma

Anti-IgE therapy. Omalizumab (Xolair) was the first approved biological therapy for severe asthma (in 2003). It is a recombinant humanized IgG1 monoclonal antibody that binds to free IgE and down regulates the inflammatory cascade. It is therefore best suited for patients with early-onset allergic asthma with a high IgE count. The dose and frequency (once or twice per month) of omalizumab are based on IgE levels and patient weight. Omalizumab reduces asthma exacerbation (up to 45%) and hospitalization (up to 85%).34 Omalizumab also reduces the need for high-dose ICS-LABA therapy and improves quality of life (QoL).33,34

Continue to: Its efficacy and safety...

Pages

Recommended Reading

FDA okays Palforzia, first drug for peanut allergy in children
MDedge Family Medicine
FDA okays first generic of ProAir HFA
MDedge Family Medicine
Can this patient get IV contrast?
MDedge Family Medicine
FDA issues stronger warning on neuropsychiatric event risk linked to montelukast
MDedge Family Medicine
Study links GLP-1R agonists, lower inflammatory biomarker levels
MDedge Family Medicine
Study: Delays filling biologic prescriptions have consequences
MDedge Family Medicine
Stronger links forged between RA and asthma, COPD
MDedge Family Medicine
Acid-suppressant medications in infants with bronchiolitis raises later allergy risk
MDedge Family Medicine
Gene-targeting therapy shown to reduce mastocytosis symptoms
MDedge Family Medicine
Peanut OIT-induced eosinophilia may eventually resolve
MDedge Family Medicine